Public Company Edition: Several special purpose acquisition corporations have emerged, including various health care- and life science-focused SPACs. Also, Alvotech entered into a $965m refinancing agreement and Avidity grossed $461m in a follow-on offering, among other updates.

The company claims its gene editing tech is the most potent yet – and is joining others in making established cardiovascular disease gene PCSK9 its first therapeutic target

Public Company Edition: Arvinas grossed $350m in a private placement, while Xenon brought in $345m and Pharvaris raised $300m in follow-on public offerings. Fundraising remains challenging, however, so IGM Biosciences, Hansa Biopharma and other companies cut costs to save money.

The San Francisco-based company has taken a step forward with proof of concept for its ‘switch on or switch off’ approach to gene regulation via non-cutting CRISPR molecules.